TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00861250
Drug: bortezomib + dexamethasone
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
Study: NCT01376102
Drug: BONVIVA(ibandronate) injection
Normalized name: Boniva
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study: NCT03447678
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: humanized antibody used in cancer immunotherapy
Study: NCT03585530
Drug: raltitrexed
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed 2.6mg/m2 was administered on d1、d22
Study: NCT04351516
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days
Study: NCT02751593
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 40mg/d for 4 days
Study: NCT01081678
Drug: Romosozumab
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by subcutaneous injection
Study: NCT01205230
Drug: pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)
Study: NCT02272777
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib 400mg QD，300mg QD or 600mg QD
Study: NCT00163267
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Best endovascular treatment either with one or the other drug arm should be investigated
Study: NCT02272777
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 300mg BID or 400mg QD
Study: NCT03965858
Drug: Esketamine DPI - low dose
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
Study: NCT03965858
Drug: Esketamine DPI - medium dose
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
Study: NCT03965858
Drug: Esketamine DPI - high dose
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
Study: NCT00657865
Drug: ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral intake
Study: NCT04062019
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 once every other day, for 3 months.
Study: NCT02819635
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Film-coated tablet for oral administration
Study: NCT01687179
Drug: Sirolimus and Hydroxychloroquine 200 mg
Normalized name: Sirolimus
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This will be a phase I dose escalation study of the combination of Sirolimus (2 mg adjusted to keep trough levels between 5-15 ng/ml) and Hydroxychloroquine 200 mg taken orally daily.
Study: NCT01687179
Drug: Sirolimus and Hydroxychloroquine 400 mg
Normalized name: Sirolimus
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once safety is established with the lower dose, (Sirolimus and Hydroxychloroquine 200 mg), subjects will receive Sirolimus 2 mg (adjusted to keep trough levels between 5 to 15 ng/ml) and hydroxychloroquine 200 mg twice a day.
Study: NCT01011439
Drug: Milciclib Maleate
Normalized name: Milciclib Maleate
DrugBank: Milciclib Maleate (DB16232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity.
Study: NCT01312454
Drug: AL-59412C injectable solution
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentration 1 and Concentration 2
Study: NCT01312454
Drug: Travoprost injectable solution
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01312454
Drug: AL-59412C Vehicle
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients used as placebo
Study: NCT00139282
Drug: Squalamine Lactate
Normalized name: Squalamine
DrugBank: Squalamine (DB06461)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02057796
Drug: Rifampin, isoniazid, pyrazinamide, ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization
Study: NCT00659399
Drug: Fondaparinux
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arixtra 2.5 mg by subcutaneous injection once daily for 8 weeks or until disease recurrence or grade 3, 4 adverse events.
Study: NCT02066311
Drug: Nelfinavir
Normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02319668
Drug: 0.2% w/v Chlorhexidine digluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will brush their teeth with the reference product (toothpaste) and thoroughly rinse their mouth with water and wait 5 timed minutes before using 10 ml of the 0.2% w/v Chlorhexidine digluconate mouthwash, except when using at site, where no brushing will take place prior to using the mouthrinse.
Study: NCT02319668
Drug: Sodium fluoride toothpaste (Aquafresh Mild & Minty)
Normalized name: sodium fluoride Toothpaste
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
Study: NCT00117546
Drug: alpha methyldopa
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg twice a day
Study: NCT02475070
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks
Study: NCT02475070
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks
Study: NCT00865696
Drug: Mirtazapine 15 mg tablets, single dose
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Study: NCT00004047
Drug: exatecan mesylate
Normalized name: mesylate
DrugBank: Exatecan (DB12185)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02621060
Drug: Chlorogenic acid
Normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chologenic acid: 1200 mg per day for three months
Study: NCT01471470
Drug: Docetaxel, Capecitabine, Cisplatin, Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
Study: NCT03991000
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous iron
Study: NCT03991000
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline application according to dosing rules of iron.
Study: NCT03092206
Drug: F/TAF
Normalized name: Emtricitabine/Tenofovir Alafenamide
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: antiretroviral therapy
Study: NCT01101880
Drug: clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01101880
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04329403
Drug: Adapalene 0.1% Gel
Normalized name: ADAPALENE 0.1% GEL,TOP
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
Study: NCT01750931
Drug: Mobic 15mg
Normalized name: Mobic 15mg Tablet
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \& Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
Study: NCT02512809
Drug: Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02512809
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03241199
Drug: Imatinib Mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: a first-generation tyrosine kinase inhibitors
Study: NCT02207998
Drug: Homeopathic complex and physiotherapy
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homoeopathic complex (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of medicated lactose tablets.
Study: NCT04001075
Drug: TJ107
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period
Study: NCT01921920
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
Study: NCT00724256
Drug: ceftibuten
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ceftibuten 9mg/kg once a day for 7 days.
Study: NCT00724256
Drug: ceftibuten
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ceftibuten 9mg/kg once a day for 10 days.
Study: NCT02086188
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see detailed information in associated Arm Description
Study: NCT01970046
Drug: Placebo/Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks~* Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks~* Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks
Study: NCT01149629
Drug: Droxidopa
Normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule containing 300 mg droxidopa, given once
Study: NCT01149629
Drug: Droxidopa
Normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals
Study: NCT01149629
Drug: Droxidopa
Normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 capsules each containing 100 mg droxidopa, given once
Study: NCT01638988
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1. cycle 2000 mg of Metformin : Day 1 to day 30; beginning with 1/2 tablet by day with an increasing until 4 pills by day~2. to 6 cycle 2000 mg of Metformin : Day 1 ot day 30; 4 pills of Metformin by day Positive pregnancy test : 4 pills of Metformin by day until 12 weeks of pregnancy
Study: NCT01638988
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycle 1: Day 3 to day 7; 50 mg; 1 tablet of Clomiphene Citrate by day Cycle 2: Day 3 to day 7; 100 mg; 1 tablet of Clomiphene Citrate two times a day Cycle 3 to 6 : Day 3 to day 7; 150 mg; 1 tablet of Clomiphene Citrate 3 times a day
Study: NCT00150293
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01378104
Drug: peginterferon alfa 2a (pegasys)
Normalized name: Peginterferon Alfa-2A
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable
Study: NCT01378104
Drug: peginterferon alfa-2a (pegasys)
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
Study: NCT02290626
Drug: Elmental diet
Normalized name: casein, emmental cultured
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: elemental diet is administered using PEG.
Study: NCT01536951
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03471078
Drug: Avatrombopag
Normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral avatrombopag tablet
Study: NCT01727271
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01938547
Drug: clevidipine
Normalized name: Clevidipine
DrugBank: Clevidipine (DB04920)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02248597
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00514163
Drug: gemcitabine + S-1
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
Study: NCT00514163
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine DIV on day one , 8th and 15th
Study: NCT00397033
Drug: Paliperidone ER
Normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6mg/day paliperidone er for 6 weeks
Study: NCT00397033
Drug: Paliperidone ER
Normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12mg/day paliperidone er for 6 weeks
Study: NCT01564407
Drug: ICX-RHY-013
Normalized name: ICX-RHY
DrugBank: ICX-RHY (DB05716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Dosing for Cohorts as follows:~Cohorts (N=4)~Safety Cohort 1:~1. Empty control no injection~2. Vehicle only (0.5 ml of HypoThermosol solution)~3. 5 million cells / cm² , single administration at Day 0~4. 5 million cells/ cm² , single administration at week 4~5. 5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4~At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.~Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks
Study: NCT02248597
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02248597
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02248597
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02836847
Drug: GEMOX
Normalized name: Hemox A
DrugBank: Aluminum chloride (DB11081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy:gemcitabine and oxaliplatin
Study: NCT02836847
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02836847
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02836847
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00078325
Drug: Armodafinil 250 mg/day
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Armodafinil 250 mg once daily in the morning
Study: NCT00078325
Drug: Armodafinil 150 mg/day
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Armodafinil 150 mg once daily in the morning
Study: NCT01473563
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT00502346
Drug: PM10
Normalized name: VPM1002
DrugBank: VPM1002 (DB15801)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01001468
Drug: VB-201
Normalized name: VB-201
DrugBank: VB-201 (DB15259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of oral VB-201 20 mg
Study: NCT02836847
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02836847
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02836847
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02836847
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04587778
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT04587778
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous infusion
Study: NCT01001468
Drug: VB-201
Normalized name: VB-201
DrugBank: VB-201 (DB15259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose or oral VB-201 80 mg
Study: NCT03054922
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of lactated ringer throughout surgery.
Study: NCT04587778
Drug: Pilot study II: Esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT01269801
Drug: onabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: * Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~* Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment.
Study: NCT05513625
Drug: Pritelivir
Normalized name: Pritelivir
DrugBank: Pritelivir (DB11844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT05513625
Drug: ESO and pritelivir
Normalized name: cytarabine and daunorubicin
DrugBank: Pritelivir (DB11844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT02693522
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT02693522
Drug: Eutropin
Normalized name: lutropin alfa
DrugBank: Lutropin alfa (DB00044)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT03574753
Drug: ABBV-399
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-399 (Process II), 2.7 mg/kg IV over 30 ± 10 minutes, Day 1, Every 21 days
Study: NCT00020618
Drug: morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01037660
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1 gram per day
Study: NCT01970046
Drug: SP2086 50 mg b.i.d/Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks~* Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks
Study: NCT00121433
Drug: leptin
Normalized name: Leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no